SAFC and Novozymes Biopharma extend joint agreement for the exclusive distribution of LONGR3 growth factor
SAFC, a member of the Sigma-Aldrich Group, and Novozymes Biopharma DK A/S announced a 10-year extension of their joint agreement under which SAFC retains exclusive marketing and distribution rights for Novozymes Biopharma's LONGR³IGF-I (LONGR3) growth factor used for industrial cell culture applications. The highly potent growth factor is manufactured specifically for customers in the cell culture market, to enable them to reduce operational and regulatory complexity and minimize manufacturing risk.
Michael D. James, marketing manager, SAFC, said, "SAFC is thrilled to continue our collaboration with Novozymes Biopharma. This exclusive 10-year agreement is expected to enhance SAFC's market-leading position as a critical raw material supplier into the biologic and vaccine markets. It is exciting to see how the unique attributes of LONGR3 meet key development and manufacturing challenges as cell culture processes continue to become more sophisticated."
Other news from the department business & finance
